文献速递基础与转化研究临床试验与 GCP

体内碱基编辑基因治疗杂合性家族性高胆固醇血症:1期试验

In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial.
PubMed 文献 · Nat Med · 2026-03-03

YOLT-101是一种经GalNAc修饰脂质纳米颗粒递送的腺嘌呤碱基编辑体内基因疗法,旨在灭活PCSK9并持续降低LDL-C。本1期试验中期结果显示,6例杂合性家族性高胆固醇血症成人接受单次静脉递增剂量(0.2、0.4或0.6 mg kg-1)后,无≥3级不良事件。0.6 mg kg-1队列(n=3)24周时PCSK9和LDL-C分别持续降低74.4%和52.3%。

要点

  • 单次静脉YOLT-101在0.6 mg kg-1队列24周时PCSK9降低74.4%、LDL-C降低52.3%。
  • 6例受试者中无≥3级不良事件,常见为短暂自限性输注反应和肝酶升高。
  • YOLT-101降低PCSK9和LDL-C呈剂量依赖且持久。

核心结论

  • 单次静脉YOLT-101在杂合性家族性高胆固醇血症成人中诱导剂量依赖且持久的PCSK9和LDL-C降低,0.6 mg kg-1队列24周时分别持续降低74.4%和52.3%。

研究设计与样本

  • 正在进行的临床试验中期结果,评估单次静脉YOLT-101在杂合性家族性高胆固醇血症且LDL-C未控制的成人中的主要结局(安全性和耐受性)和次要结局(PCSK9和LDL-C水平降低)。
  • 6例受试者(3男3女)接受递增剂量YOLT-101(0.2、0.4或0.6 mg kg-1)。

主要发现

  • 无≥3级不良事件发生。
  • 短暂且自限的输注相关反应和肝酶升高是最常见的不良事件。
  • 单次输注YOLT-101诱导剂量依赖且持久的循环PCSK9和LDL-C降低,0.6 mg kg-1队列(n=3)24周时分别持续降低74.4%和52.3%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heterozygous familial hypercholesterolemia is a common genetic disorder characterized by lifelong elevation of serum low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. YOLT-101 is an investigational in vivo gene therapy that uses adenine base-editing technology, delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9 and achieve sustained LDL-C reduction. Here we report interim results from an ongoing clinical trial evaluating primary (safety and tolerability) and secondary (lowering of PCSK9 and LDL-C levels) outcomes of a single intravenous dose of YOLT-101 in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL-C. Six participants (three men and three women) received escalating doses of YOLT-101 (0.2, 0.4 or 0.6 mg kg-1). No grade ≥3 adverse events occurred. Transient and self-limited infusion-related reactions and elevations in liver enzymes were the most common adverse events. A single infusion of YOLT-101 induced dose-dependent and durable reductions in circulating PCSK9 and LDL-C, with sustained reductions of 74.4% and 52.3%, respectively, at 24 weeks in the 0.6 mg kg-1 cohort (n = 3), demonstrating promise for future clinical development. ClinicalTrials.gov registration: NCT06458010 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Wan P, Tang S, Lin D, et al. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat Med. 2026. PMID: 41776075. doi:10.1038/s41591-026-04254-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。